MINOLIRA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINOLIRA (MINOLIRA).
Sodium-glucose co-transporter-2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
| Metabolism | Primarily metabolized via glucuronidation by UGT1A9, UGT2B4, and UGT1A1; minor metabolism via CYP enzymes (CYP3A4, CYP2C8). |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 25%; the remainder undergoes hepatic metabolism. |
| Half-life | Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | ~85% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5–0.8 L/kg, suggesting moderate tissue distribution. |
| Bioavailability | Oral: 70–80% (first-pass metabolism reduces absolute bioavailability to ~75%). |
| Onset of Action | Oral: 1–2 hours; Intravenous: within 5–10 minutes. |
| Duration of Action | Oral: 8–12 hours for therapeutic effect; Intravenous: 4–6 hours post-infusion. |
| Molecular Weight | 321.37 |
60 mg subcutaneously once daily
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild-to-moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), reduce dose to 30 mg subcutaneously once daily. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate-to-severe hepatic impairment (Child-Pugh B or C), reduce dose to 30 mg subcutaneously once daily. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function in elderly as age-related decline may necessitate dose reduction. |
| 1st trimester | Contraindicated: potential for teratogenicity. |
| 2nd trimester | Contraindicated: risk of fetal harm. |
| 3rd trimester | Contraindicated: risk of neonatal complications. |
Clinical note
Comprehensive clinical and safety monograph for MINOLIRA (MINOLIRA).
| Placental transfer | Crosses placenta; detected in fetal plasma at concentrations similar to maternal. |
| Breastfeeding | Excreted in breast milk; contraindicated due to potential serious adverse reactions in nursing infants. |
| Lactation Rating | L5 |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to minolira
| Precautions | Ketoacidosis (including euglycemic ketoacidosis), Acute kidney injury and need for monitoring of renal function, Volume depletion, hypotension, and electrolyte abnormalities, Urosepsis and pyelonephritis, Lower limb amputation (increased risk with prior amputation, peripheral vascular disease, neuropathy), Genital mycotic infections |
| Food/Dietary | Avoid concomitant ingestion of dairy products (milk, yogurt, cheese), antacids containing aluminum, calcium, or magnesium, iron supplements, calcium supplements, and bismuth subsalicylate within 2 hours of minocycline administration, as these can chelate the drug and significantly reduce its absorption. Alcohol can increase risk of vestibular adverse effects and hepatotoxicity; limit or avoid alcohol consumption. |
Loading safety data…
| Teratogenic Risk | MINOLIRA (minocycline) is contraindicated in pregnancy. First trimester: Associated with central nervous system anomalies, including neural tube defects and hydrocephalus, and cardiovascular malformations. Second/third trimester: Causes reversible inhibition of fetal bone growth and permanent tooth discoloration (yellow-gray-brown). Risk of maternal hepatotoxicity and pancreatitis is increased during pregnancy. |
| Fetal Monitoring | Maternal: Liver function tests (AST, ALT, bilirubin), renal function, and complete blood count (due to risk of neutropenia and thrombocytopenia). Fetal: Ultrasound for fetal growth and development if inadvertent exposure occurs. Neonatal: Observe for hyperbilirubinemia and kernicterus (due to displacement of bilirubin from albumin). |
| Fertility Effects | Minocycline may impair female fertility by inhibiting implantation and trophoblast growth in animal studies. Human data are limited but suggest potential reversible effects on ovulation and spermatogenesis. Caution in couples attempting conception; use effective contraception during therapy. |
| Clinical Pearls | Minolira (minocycline) is a tetracycline antibiotic with high lipophilicity, achieving excellent tissue penetration. It is associated with vestibular adverse effects (dizziness, vertigo, ataxia) more frequently than other tetracyclines; warn patients not to drive or operate machinery if affected. It can also cause benign intracranial hypertension (pseudotumor cerebri), especially in women of childbearing age; monitor for headache and visual disturbances. Minocycline hyperpigmentation can occur in skin, nails, oral mucosa, and bones, often after long-term use; it is irreversible but usually cosmetic. It has anti-inflammatory properties independent of antimicrobial effects, making it useful in acne vulgaris and rheumatoid arthritis. Avoid use in pregnancy (pregnancy category D) and children under 8 years due to permanent tooth discoloration and bone growth inhibition. Contraceptives may be less effective; advise additional barrier methods. |
| Patient Advice | Take minocycline exactly as prescribed, usually every 12 hours, with a full glass of water. You may take it with or without food, but avoid taking it with dairy products, antacids, or iron supplements within 2 hours, as they can reduce absorption. · Do not take this drug if you are pregnant, planning to become pregnant, or breastfeeding. It can harm the unborn baby and cause permanent teeth discoloration in developing children. · Minocycline may cause dizziness, lightheadedness, or vertigo. Do not drive, operate machinery, or perform hazardous activities until you know how this medication affects you. · Report any persistent headache, vision changes, or blurred vision immediately, as these could be signs of increased intracranial pressure. · You may notice skin, nail, or oral mucosa discoloration (blue-black or gray spots) after long-term use. This is usually harmless but may be permanent. · Complete the full course of treatment even if you feel better, unless directed otherwise by your doctor to prevent antibiotic resistance. · Use effective contraception while taking this medication; oral contraceptives may be less effective. · Avoid excessive sun exposure and use sunscreen, as minocycline can increase sensitivity to sunlight (photosensitivity). |